Medicament carrier solution for abdominal cavity chemotherapy and pharmaceutical composition thereof

Abstract

The invention provides a medium-molecular-weight hydroxyethylated starches applied to abdominal cavity chemotherapy drug carrier agent, wherein the molecular weight Mw of the medium-molecular-weight hydroxyethylated starches is 60000-600000 dalton, molar degree of substitution is 0. 15-0. 5 and hydroxyethylating substitution ratio in C2 and C6 is >=5. The invention provides carrier liquid including the medium-molecular-weight hydroxyethylated starches and the chemotherapy drug to make the big bulk extend existing time in the abdominal cavity with lasting high concentration through using the carrier liquid, which can contact the drug with the visceral and peritoneal surface in a large area to invade the remained nodules and caner stove to enhance antineoplastic effect to reduce the abdominal cavity adhesion.

Description

technical field [0001] The invention relates to a drug carrier solution and a drug composition for intraperitoneal chemotherapy. Background technique [0002] Gastrointestinal malignancy is a common malignant tumor in clinical practice. In the past 30 years, despite the continuous improvement of surgical methods and the development of radiotherapy, chemotherapy, biological immunotherapy and traditional Chinese medicine, the prognosis and mortality of patients with gastrointestinal malignancy have not been improved. Significantly improved, the 5-year survival rate of gastric cancer is only 46%, and the 5-year survival rate of colorectal cancer is only 50%. The recurrence and metastasis rates of colorectal cancer are 30-80% and 37%, respectively. The common sites of recurrence and metastasis of gastrointestinal malignant tumors are the resection site, peritoneal surface and liver in sequence. Intraperitoneal chemotherapy targets this biological behavior, allowing anticancer d...

AI Technical Summary

Problems solved by technology

[0003] However, there are still two major problems in intraperitoneal chemotherapy: one is the penetration of anticancer drugs; the other is the problem of maintaining a constant and long-lasting high concentration of intraperitoneal chemotherapy carrier

Due to the lack of various metabolic enzymes in the abdominal cavity, when the molecular weight of the colloidal component increases, it will cause the problem that the component is difficult to degrade

When the drainage is not smooth after treatment, the polymer remains in the corner of the abdominal cavity for too long, which may lead to complications such as infection